Wednesday, August 26, 2015

Growing Intrauterine Contraceptive Device Industry

The global intra-uterine contraceptive devices (IUCD) market was valued at $3,314.6 million in 2014, which is expected to reach a value of $4,605.6 million by 2019, at a CAGR of 6.8% from 2014 to 2019.

The global intrauterine contraceptive devices market is segmented on the basis of type which includes hormonal IUCD and copper IUCD. The copper IUCD segment contributed for the maximum share of 51.9% in 2014, followed by hormonal IUCD with 48.1% share. On the basis of products, this market has been segmented into Mirena, Skyla, ParaGuard, and Essure. In terms of geography, the market covered regions, such as Asia, Europe, North America, and Rest of the World (ROW).
Get a PDF File

The growth of the intrauterine contraceptive devices market is driven by factors such as rising rate of unplanned pregnancies, effective contraception and minimum side effects of IUCD, implementation of Affordable Care Act (ACA), higher number of initiatives undertaken by private firms directed towards reducing the expenses related to abortion, and technological advancements.

The main companies operating in Intrauterine Contraceptive Device Industry are 
  • Bayer HealthCare AG (A subsidiary of BAYER AG) (Germany)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Actavis Plc. (Ireland)
  • Medicines360 (Ireland)

No comments:

Post a Comment